根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在每个月的前三个交易日内披露截至上月末的回购进展情况。现 将公司截至上月末的回购进展情况公告如下： 一、回购公司股份实施进展情况 截至 2025 年 1 月 31 日，公司通过回购专用账户以集中竞价方式回购公司股 份 426,000 股，占公司总股本的 0.17%，最高成交价为 12.73 元/股，最低成交价 为 9.86 元/股，成交总金额为 4,782,041.00 元（不含交易费用）。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年3月8日召开 第二届董事会第二次会议、第二届监事会第二次会议，于2024年3月25日召开2024 年第一次临时股东大会，审议通过了《关于回购公司股份方案的议案》。公司使 用自有资金以集中竞价交易方式回购公司部分人民币普通股A股股份，用于员工 持股计划或者股权激励，回购资金总额不低于人民币1,500万元（含）且不超过 3,000万元（含）。回购价格不超过人民币20.00元/股，回购 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of 20 million to 28 million yuan for 2024, compared to a loss of 42.94 million yuan in the same period last year[3] - The profit after deducting non-recurring gains and losses is projected to be between 8 million and 18 million yuan, improving from a loss of 52.90 million yuan in the previous year[3] - Basic earnings per share are anticipated to be between 0.0820 yuan and 0.1149 yuan, recovering from a loss of 0.1761 yuan per share last year[3] - The performance forecast has been communicated with the accounting firm, and no significant discrepancies were found[4] - Investors are advised to exercise caution as the performance forecast is based on preliminary estimates and the final financial data will be disclosed in the 2024 annual report[6] Market Expansion and Product Development - The company has successfully launched new products, leading to a significant increase in order volume[5] - The company has made notable progress in expanding its overseas market presence, particularly in offline supermarket channels[5] - New domestic customers have been successfully introduced, contributing to the growth of product orders and market share[5] - The replenishment demand from downstream customers, following successful inventory destocking in 2023, is expected to positively impact the company's performance in 2024[5]

证券代码：001300 证券简称：三柏硕 公告编号：2024-058 青岛三柏硕健康科技股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年3月8日召开 第二届董事会第二次会议、第二届监事会第二次会议，于2024年3月25日召开2024 年第一次临时股东大会，审议通过了《关于回购公司股份方案的议案》。公司使 用自有资金以集中竞价交易方式回购公司部分人民币普通股A股股份，用于员工 持股计划或者股权激励，回购资金总额不低于人民币1,500万元（含）且不超过 3,000万元（含）。回购价格不超过人民币20.00元/股，回购股份的实施期限自 股东大会审议通过本次回购股份方案之日起不超过12个月。具体内容详见公司刊 登在《证券时报》《证券日报》《中国证券报》《上海证券报》《经济参考报》 和巨潮资讯网（www.cninfo.com.cn）的《关于回购公司股份方案的公告》（公 告编号：2024-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 ...

证券代码： 001300 证券简称：三柏硕 投资者关系活动记录表 青岛三柏硕健康科技股份有限公司 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------|--------------| | | □ 分析师会议 | | | | □ 业绩说明会 | | | 投资者关系活动 类别 | □ 路演活动 | | | | 年青岛辖区上市公司投资者网上集体接待日活动） | | | 参与单位名称及 人员姓名 | | | | 时间 | 周四 ) 下午 15:00~17:00 | | | 地点 | 公司通过中国证券报中证网（ https://www.cs.com.cn | ）采用网 | | 上市公司接待人 | | | | 员姓名 | 投资者提出的问题及公司回复情况 公司就投资者在本次活动中提出的问题进行了回复： | | | | 、请问贵公司回购进展怎么样了？ | | | | 尊敬的投资者，您好。根据公司公告：截至 2024 年 | ...

Group 1: Event Announcement - Qingdao Sanbai Shuo Health Technology Co., Ltd. will participate in the "2024 Qingdao District Listed Companies Investor Online Collective Reception Day" [2] - The event will be held online on November 28, 2024, from 15:00 to 17:00 [2] - Investors can participate through the China Securities Journal website [2] Group 2: Key Participants - The company's General Manager, Mr. Wen Ke, will be present for the online communication [2] - The Board Secretary, Mr. Fang Ruizheng, and the Chief Financial Officer, Mr. Wu Zhiqiang, will also participate [2] Group 3: Discussion Topics - The discussion will cover corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2]

证券代码：001300 证券简称：三柏硕 公告编号：2024-056 本次回购符合公司既定回购方案以及相关法律法规的要求。 二、其他说明 公司回购股份的时间、回购股份的数量、回购股份价格及集中竞价交易的 委托时段均符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监 青岛三柏硕健康科技股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年3月8日召开 第二届董事会第二次会议、第二届监事会第二次会议，于2024年3月25日召开2024 年第一次临时股东大会，审议通过了《关于回购公司股份方案的议案》。公司使 用自有资金以集中竞价交易方式回购公司部分人民币普通股A股股份，用于员工 持股计划或者股权激励，回购资金总额不低于人民币1,500万元（含）且不超过 3,000万元（含）。回购价格不超过人民币20.00元/股，回购股份的实施期限自 股东大会审议通过本次回购股份方案之日起不超过12个月。具体内容详见公司刊 登在《证券时报》《证券日报》《中国证券报》《上海证券报》 ...

法律意见书 二〇二四年十月 北京 •上海 •深圳 •广州 •成都 •武汉 •重庆 •青岛 •杭州 •香港 •东京 •伦敦 •纽约 •洛杉矶 •旧金山 Beijing • Shanghai • Shenzhen • Guangzhou • Chengdu • Wuhan • Chongqing • Qingdao • Hangzhou • Hong Kong • Tokyo • London • New York •Los Angeles• San Francisco 北京市中伦（青岛）律师事务所 关于青岛三柏硕健康科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 致：青岛三柏硕健康科技股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受青岛三柏硕健康科 技股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前已经发 生或存在的事实和《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 《律师事务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则 （试行）》等中华人民共和国（以下简称"中 ...

证券代码：001300 证券简称：三柏硕 公告编号：2024-055 青岛三柏硕健康科技股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决、修改、增加议案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1. 召开时间： 3. 召开方式：本次股东大会采用现场投票与网络投票相结合的方式。 （1）现场投票：现场出席及通过填写授权委托书授权他人出席。 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向公司股东提供网络形式的投票平台，公司股 东可以在上述网络投票时间内通过上述系统行使表决权。公司股东只能选择现场 投票和网络投票中的一种表决方式，表决结果以第一次有效投票结果为准。 4. 会议召集人：公司董事会。 5. 会议主持人：董事长朱希龙先生。 （1）现场会议时间：2024 年 10 月 31 日下午 14:00。 （2）网络投票时间：2024 年 10 月 31 日。其 ...

Revenue and Profitability - The company's revenue for Q3 2024 reached ¥131,724,251.65, representing a 28.77% increase year-over-year[3] - Net profit attributable to shareholders decreased by 33.50% to ¥2,191,754.38 in Q3 2024, while year-to-date net profit increased by 70.85% to ¥20,680,616.69[3] - The company's basic and diluted earnings per share for Q3 2024 were both ¥0.0090, down 33.33% from the same period last year[3] - The company reported a 37.66% increase in year-to-date revenue, totaling ¥399,844,406.71, driven by higher order volumes[6] - Total operating revenue for Q3 2024 reached CNY 399,844,406.71, a significant increase of 37.7% compared to CNY 290,462,906.26 in the same period last year[13] - Net profit attributable to shareholders for Q3 2024 was CNY 20,680,616.69, compared to CNY 12,104,226.81 in Q3 2023, representing an increase of 70.8%[14] - Basic and diluted earnings per share for the current period were CNY 0.0848, compared to CNY 0.0497 in the previous period, reflecting a year-over-year increase of 70.5%[15] Cash Flow and Financial Position - The net cash flow from operating activities for the year-to-date period was -¥29,461,238.35, a decline of 173.45% compared to the previous year[3] - The company reported a net cash inflow from other operating activities of CNY 5,832,756.97, an increase of 107.85% compared to the previous period[7] - Cash inflows from operating activities totaled CNY 401,946,787.42, up from CNY 339,201,766.07 in the previous period, indicating a growth of about 18.5%[17] - Cash outflows from operating activities were CNY 431,408,025.77, compared to CNY 349,975,530.02 in the previous period, resulting in a net cash flow from operating activities of CNY -29,461,238.35[17] - The company reported cash and cash equivalents at the end of the period of CNY 220,367,480.73, down from CNY 525,806,726.74 in the previous period, a decrease of approximately 58.2%[18] - The company experienced a significant decrease in cash recovered from the disposal of fixed and intangible assets, down 76.85% to CNY 46,766.00[7] - The impact of exchange rate fluctuations on cash was negative, amounting to CNY -2,535,228.40, a decline of 205.38% compared to the previous period[7] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥1,284,159,195.89, reflecting a 7.08% increase from the end of the previous year[3] - The company's total assets increased to CNY 1,284,159,195.89 from CNY 1,199,263,425.05, marking a growth of 7.1% year-over-year[13] - The company's total liabilities reached CNY 228,739,386.42, compared to CNY 163,170,024.89, which is an increase of 40.2%[13] - The total equity attributable to shareholders increased to CNY 1,055,419,809.47 from CNY 1,036,093,400.16, reflecting a growth of 1.9%[13] Expenses and Investments - Total operating costs amounted to CNY 390,838,660.40, up from CNY 287,442,748.93, reflecting a year-over-year increase of 36%[14] - Research and development expenses for Q3 2024 were CNY 19,153,970.44, up from CNY 15,780,517.61, showing a growth of 21.5%[14] - The company experienced a significant increase in financial expenses, with a 58.63% rise due to increased exchange gains and losses[6] - Investment cash outflows rose by 73.06% to CNY 1,799,788,141.93, primarily due to increased financial product purchases[7] - Investment activities resulted in a net cash outflow of CNY -114,077,958.81, compared to a net inflow of CNY 255,575,974.66 in the previous period[17] - Cash inflows from investment activities were CNY 1,694,243,844.46, an increase from CNY 1,315,771,881.35 in the previous period, showing a growth of about 28.8%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,494, with the top ten shareholders holding a combined 73.03% of shares[8] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of the shares, totaling 115,317,531 shares[8] - The company repurchased 151,000 shares, representing 0.06% of total share capital, with a total transaction amount of CNY 1,507,358.00[10] Taxation - Tax payments increased by 48.21% to CNY 10,918,067.20 due to higher tax obligations in the current period[7] - The company received tax refunds amounting to CNY 33,202,405.84, compared to CNY 30,583,944.59 in the previous period, reflecting an increase of about 5.3%[17] Non-Operating Income - Non-operating income for Q3 2024 totaled ¥460,368.71, a 114.12% increase compared to the same period last year[6] - The company reported a financial income of CNY 6,095,388.14, compared to CNY 3,366,207.83 in the previous year, an increase of 80.7%[14]

中信建投证券股份有限公司 注销部分募集资金专户的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为青岛三柏硕健康科技股份有限公司（以下简称"三柏硕"或"公司"）首次 公开发行股票并上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对三柏硕部分募投项目结项并将节余募集资金永 久补充流动资金及注销部分募集资金专户事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准青岛三柏硕健康科技股份有限公司首 次公开发行股票的批复》（证监许可〔2022〕2054 号）核准，青岛三柏硕健康科 技股份有限公司首次公开发行人民币普通股（A 股）股票 60,943,979 股，每股面 值 1.00 元，每股发行价格为人民币 11.17 元，募集资金总额为人民币 680,744,245.43 元，扣除相关发行 ...